Ana María Arbeláez

Ana María Arbeláez

Auto-generated profile, based on publicly available information

Ana María Arbeláez

Division of Pediatric Endocrinology, Washington University School of Medicine in St. Louis, St. Louis, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Diabetes Care
Verified
Journal Article
Open access
PDF file
NMNelly Mauras
Nelly Mauras
BBBruce Buckingham
Bruce Buckingham
NWNeil H. White
Neil H. White
ETEva Tsalikian
Eva Tsalikian
SWStuart A. Weinzimer
Stuart A. Weinzimer
ARAllan L. Reiss
Allan L. Reiss
OBJECTIVE: To assess whether previously observed brain and cognitive differences between children with type 1 diabetes and control subjects without diabetes persist, worsen, or improve as children grow into puberty and whether differences are associated with hyperglycemia. RESEARCH DESIGN AND METHODS: One hundred forty-four children with type 1 diabetes and 72 age-matched control subjects without diabetes (mean ± SD age at baseline 7.0 ± 1.7 years, 46% female) had unsedated MRI and cognitive testing up to four times over 6.4 ± 0.4 (range 5.3–7.8) years; HbA1c and continuous glucose monitoring were done quarterly. FreeSurfer-derived brain volumes and cognitive metrics assessed longitudinally were compared between groups using mixed-effects models at 6, 8, 10, and 12 years. Correlations with glycemia were performed. RESULTS: Total brain, gray, and white matter volumes and full-scale and verbal intelligence quotients (IQs) were lower in the diabetes group at 6, 8, 10, and 12 years, with estimated group differences in full-scale IQ of −4.15, −3.81, −3.46, and −3.11, respectively (P < 0.05), and total brain volume differences of −15,410, −21,159, −25,548, and −28,577 mm3 at 6, 8, 10, and 12 years, respectively (P < 0.05). Differences at baseline persisted or increased over time, and brain volumes and cognitive scores negatively correlated with a life-long HbA1c index and higher sensor glucose in diabetes. CONCLUSIONS: Detectable changes in brain volumes and cognitive scores persist over time in children with early-onset type 1 diabetes followed longitudinally; these differences are associated with metrics of hyperglycemia. Whether these changes can be reversed with scrupulous diabetes control requires further study. These longitudinal data support the hypothesis that the brain is a target of diabetes complications in young children.

17 September 2015 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
KSKatherine Semenkovich
Katherine Semenkovich
ABAllison Bischoff
Allison Bischoff
TDTasha Doty
Tasha Doty
SNSuzanne Nelson
Suzanne Nelson
ASAlejandro F Siller
Alejandro F Siller
AAAna Maria Arbeláez
Ana Maria Arbeláez

14 July 2015 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
KSK. Semenkovich
K. Semenkovich
PPP. P. Patel
P. P. Patel
APA. B. Pollock
A. B. Pollock
KBK. A. Beach
K. A. Beach
SNS. Nelson
S. Nelson
AAA. M. Arbeláez
A. M. Arbeláez

30 March 2012 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PDF file
TJTara Christine Jackson
Tara Christine Jackson
MKMelissa Jo Krauss
Melissa Jo Krauss
MDMichael Rutledge DeBaun
Michael Rutledge DeBaun
RSRobert Charles Strunk
Robert Charles Strunk
AAAna Maria Arbeláez
Ana Maria Arbeláez
Vitamin D deficiency is known to be common among patients with sickle cell anemia (SCA). Vitamin D levels were measured in 139 children (aged 7.9 to 15.1 years) to study its association with SCA morbidities; severe deficiency 30 ng/mL). Vitamin D levels were associated with pulmonary function (forced expiratory volume in 1 second [FEV1]), but not associated with either rates of acute pain or acute chest syndrome episodes. Further studies are needed to be able to compare outcomes in those with deficiency to those with sufficiency, as well as to treating patients with SCA with vitamin D to better establish a possible link, if any, between vitamin D and SCA morbidity.

28 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAna Maria Arbeláez
Ana Maria Arbeláez
YSYi Su
Yi Su
JTJewell B. Thomas
Jewell B. Thomas
AHAmy C. Hauch
Amy C. Hauch
THTamara Hershey
Tamara Hershey
BABeau M. Ances
Beau M. Ances
Different brain regions sense and modulate the counterregulatory responses that can occur in response to declining plasma glucose levels. The aim of this study was to determine if changes in regional cerebral blood flow (rCBF) during hypoglycemia relative to euglycemia are similar for two imaging modalities–pulsed arterial spin labeling magnetic resonance imaging (PASL-MRI) and positron emission tomography (PET). Nine healthy non-diabetic participants underwent a hyperinsulinemic euglycemic (92±3 mg/dL) – hypoglycemic (53±1 mg/dL) clamp. Counterregulatory hormone levels were collected at each of these glycemic levels and rCBF measurements within the previously described network of hypoglycemia-responsive regions (thalamus, medial prefrontal cortex and globus pallidum) were obtained using PASL-MRI and [15O] water PET. In response to hypoglycemia, rCBF was significantly increased in the thalamus, medial prefrontal cortex, and globus pallidum compared to euglycemia for both PASL-MRI and PET methodologies. Both imaging techniques found similar increases in rCBF in the thalamus, medial prefrontal cortex, and globus pallidum in response to hypoglycemia. These brain regions may be involved in the physiologic and symptom responses to hypoglycemia. Compared to PET, PASL-MRI may provide a less invasive, less expensive method for assessing changes in rCBF during hypoglycemia without radiation exposure.

28 November 2025 in Nature Immunology
Verified
Journal Article
Open access
PDF file
NSNeetu Srivastava
Neetu Srivastava
AVAnthony N. Vomund
Anthony N. Vomund
RYRongzhen Yu
Rongzhen Yu
OPOrion J. Peterson
Orion J. Peterson
YYYuqing Yang
Yuqing Yang
XWXiaoxiao Wan
Xiaoxiao Wan
The antigenic landscape of autoimmune diabetes reflects a failure to preserve self-tolerance, yet how novel neoantigens emerge in humans remains incompletely understood. Here we designed an immunopeptidomics-based approach to probe HLA-II-bound, islet-derived neoepitopes in patients with type 1 diabetes. We uncovered a Cys→Ser transformation, conserved between mice and humans, that reshapes autoreactivity to insulin at the single-residue level. This transformation, which we call C19S, arises from oxidative remodeling of insulin in stressed pancreatic islets and also occurs in cytokine-activated antigen-presenting cells, contributing to a feed-forward loop of neoepitope formation and presentation. Despite involving just one amino acid, C19S is recognized by HLA-DQ8-restricted, register-specific CD4+ T cells that expand at diabetes onset. These neoepitope-specific CD4+ T cells lack regulatory potential but acquire a poised central memory phenotype that persists throughout disease progression. These findings reveal a distinct, microenvironment-driven route of neoantigen formation that fuels sustained autoreactivity in diabetes.